The company will prioritize later-stage R&D, including potential accelerated approval for a second anti-amyloid antibody, while replacing its CEO and cutting Aduhelm commercial operations and other costs.

Shilpa Medicare’s plan for trials of an Eylea biosimilar shows the company’s ambition to leapfrog to a biosimilars-led growth strategy, one that Indian majors like Cipla and Lupin pivoted to post a successful generics program. However, the path isn’t going to be easy and Biocon/Viatris, Samsung Biologics are ahead

Biogen’s stake in Samsung Bioepis has been fully acquired by former partner Samsung Biologics, following an announcement of the deal in January.

Samsung Biologics has reiterated the importance of biosimilars to its business in the wake of its move to buy out partner Biogen’s stake in their Samsung Bioepis biosimilars joint venture.